STOCK TITAN

Legend Biotech CEO Ingrid Zhang buys 20,000 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Legend Biotech Corp (LEGN) CEO Ingrid Zhang purchased 20,000 ordinary shares on November 17, 2026, at $8.16 per ordinary share. A footnote says that price reflects ADS purchases at $16.32 per ADS, with each ADS representing two ordinary shares. Her reported direct holdings after the purchase were 1,151,860 ordinary shares. No Rule 10b5-1 plan is reported.

Insider Zhang Ingrid
Role Chief Executive Officer
Bought 20,000 shs ($163K)
Increase in Position 1.8%
Type Security Shares Price Value
Purchase Ordinary Shares F1, F2 20,000 $8.16 $163K
Holdings After Transaction: Ordinary Shares — 1,151,860 shares (Direct)
Holdings Before and After: Ordinary Shares, 1,131,860 to 1,151,860 shares (Direct)
Other Insiders: 1 other insider reported open-market purchases of this stock in the 30 days up to this filing.
Footnotes (2)
  1. F1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer.
  2. F2. The price reported in Column 4 represents the converted purchase price of the ADSs of $16.32 per ADS.
Ordinary shares purchased 20,000 ordinary shares Ingrid Zhang's purchase on November 17, 2026
Purchase price $8.16 per ordinary share Price reflects the converted ADS purchase price
ADS purchase price $16.32 per ADS Each ADS represents two ordinary shares
Direct holdings after purchase 1,151,860 ordinary shares Ingrid Zhang's reported position after the transaction
American Depositary Shares technical
"may be represented by American Depositary Shares"
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did LEGN CEO Ingrid Zhang buy, and at what price?

Ingrid Zhang purchased 20,000 ordinary shares at $8.16 per ordinary share on November 17, 2026. The price reflects ADS purchases at $16.32 per ADS, and each ADS represents two ordinary shares. Her reported direct holdings afterward were 1,151,860 ordinary shares. No Rule 10b5-1 plan is reported.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Zhang Ingrid

(Last)(First)(Middle)
C/O LEGEND BIOTECH CORP
77 CORPORATE DRIVE, 4TH FLOOR

(Street)
BRIDGEWATER NEW JERSEY 08807

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Legend Biotech Corp [ LEGN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/17/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Ordinary Shares(1)11/17/2026P20,000A$8.16(2)1,151,860D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer.
2. The price reported in Column 4 represents the converted purchase price of the ADSs of $16.32 per ADS.
/s/ Robert Staloff, Attorney-in-Fact11/20/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading